Skip to Content
Morningstar

Intellia Therapeutics Inc NTLA

Morningstar Rating
Unlock
Stock XNAS Rating as of
$21.50 −0.31 (1.42%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Intellia Therapeutics' Gene Editing Pipeline Looks Promising; Shares Undervalued

Rachel Elfman

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR/Cas9 has created a new class of medicines, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Read Full Report

Price vs Fair Value

View History
NTLA is trading at a 74% discount.
Price
$21.81
Fair Value
$89.00
Uncertainty
Very High
1-Star Price
$442.52
5-Star Price
$93.40
Economic Moat
Vkjgd
Capital Allocation
Ptypqflmg

Bulls Say, Bears Say

Bulls

Intellia's partnerships allow it to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

Bears

Intellia's pipeline is largely in the early stages of development and several years away from potentially receiving approval.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NTLA is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$21.81
Day Range
$21.44–22.13
52-Week Range
$21.44–47.48
Bid/Ask
$21.47 / $21.85
Market Cap
$2.07 Bil
Volume/Avg
1.1 Mil / 1.5 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
53.35
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
598
Website
https://www.intelliatx.com

Competitors

Valuation

View More
Metric
NTLA
CRSP
BNTX
Price/Earnings (Normalized)
 ——27.23
Price/Book Value
 1.932.460.92
Price/Sales
 53.3512.415.07
Price/Cash Flow
 ———
Price/Earnings
NTLA
CRSP
BNTX

Financial Strength

Metric
NTLA
CRSP
BNTX
Quick Ratio
 8.2317.419.12
Current Ratio
 8.6717.549.43
Interest Coverage
 ———
Quick Ratio
NTLA
CRSP
BNTX

Profitability

Metric
NTLA
CRSP
BNTX
Return on Assets (Normalized)
 −25.49%−3.61%3.43%
Return on Equity (Normalized)
 −30.88%−4.34%3.85%
Return on Invested Capital (Normalized)
 −31.84%−3.83%2.43%
Return on Assets
NTLA
CRSP
BNTX
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRHbmypjpdpRtfk$551.2 Bil
VRTX
Vertex Pharmaceuticals IncBvrdcmmyqHjpxgh$101.6 Bil
REGN
Regeneron Pharmaceuticals IncZqvwggmtZdvmkc$98.9 Bil
MRNA
Moderna IncXzfwrqnFntty$39.7 Bil
ARGX
argenx SE ADRBdhvzfhGvxq$22.1 Bil
BNTX
BioNTech SE ADRJjjfbjqFlh$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncGxbgktqlKrqjk$18.4 Bil
BMRN
Biomarin Pharmaceutical IncWdnhhjgcqKwqtn$17.2 Bil
RPRX
Royalty Pharma PLC Class ACnjndgzdmSqqgzr$12.3 Bil
INCY
Incyte CorpNkzzmnlfJdlvvp$11.8 Bil

Sponsor Center